Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse.
breast cancer
eosinophil
immune biomarker
immune system
lymphocyte
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
13 05 2020
13 05 2020
Historique:
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Cancer outcome is associated with circulating immune cells, including eosinophils. Here we analyze the relative eosinophil count (REC) in different breast cancer subtypes. Stage I-III breast cancer patients were included in the study and classified as REC-high vs low (cutoff 1.5%) or relative lymphocyte count (RLC)-high vs low (cutoff 17.5%). The co-primary endpoints were the breast cancer-specific survival (BCSS) or the time to treatment failure (TTF) in the REC groups. Overall 930 patients were included in the study. We observed a benefit for REC-high vs REC-low in TTF (HR 0.610, 95% CI 0.458-0.812), and in BCSS (HR 0.632, 95% CI 0.433-0.923). Similarly, we observed a better TTF (HR 0.421, 95% CI 0.262-0.677) and BCSS (HR 0.350, 95% CI 0.200-0.614) in RLC-high vs low. A lower relapse rate was observed in the REC-high REC could be a new promising, affordable and accessible predictive and prognostic biomarker in all breast cancer subtypes.
Sections du résumé
Background
Cancer outcome is associated with circulating immune cells, including eosinophils. Here we analyze the relative eosinophil count (REC) in different breast cancer subtypes.
Methods
Stage I-III breast cancer patients were included in the study and classified as REC-high vs low (cutoff 1.5%) or relative lymphocyte count (RLC)-high vs low (cutoff 17.5%). The co-primary endpoints were the breast cancer-specific survival (BCSS) or the time to treatment failure (TTF) in the REC groups.
Results
Overall 930 patients were included in the study. We observed a benefit for REC-high vs REC-low in TTF (HR 0.610, 95% CI 0.458-0.812), and in BCSS (HR 0.632, 95% CI 0.433-0.923). Similarly, we observed a better TTF (HR 0.421, 95% CI 0.262-0.677) and BCSS (HR 0.350, 95% CI 0.200-0.614) in RLC-high vs low. A lower relapse rate was observed in the REC-high
Conclusions
REC could be a new promising, affordable and accessible predictive and prognostic biomarker in all breast cancer subtypes.
Identifiants
pubmed: 32923121
doi: 10.1080/2162402X.2020.1761176
pii: 1761176
pmc: PMC7458605
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1761176Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Mol Clin Oncol. 2015 Sep;3(5):1109-1112
pubmed: 26623060
Ann Oncol. 2013 Jun;24(6):1697-703
pubmed: 23439861
Trends Cancer. 2016 Nov;2(11):664-675
pubmed: 28741505
Cancer Immunol Immunother. 2010 Jun;59(6):805-17
pubmed: 20012860
Immunotherapy. 2017 Jan;9(2):115-121
pubmed: 28128709
Jpn J Clin Oncol. 2019 May 1;49(5):431-437
pubmed: 30753621
Breast Cancer Res Treat. 2011 Nov;130(2):645-55
pubmed: 21717105
Cancer. 1976 Jan;37(1):164-8
pubmed: 1247952
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
Breast. 2012 Aug;21(4):468-74
pubmed: 22119767
Acta Oncol. 2020 Mar;59(3):257-259
pubmed: 31755328
Int J Cancer. 2014 Apr 1;134(7):1669-82
pubmed: 24105680
Ann Oncol. 2015 May;26(5):865-872
pubmed: 25070543
Int J Cancer. 2020 Mar 15;146(6):1730-1740
pubmed: 31840816
Cancer Immunol Immunother. 2012 Sep;61(9):1527-34
pubmed: 22706380
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
Laryngoscope. 2019 May;129(5):1123-1129
pubmed: 30098046
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
J Cell Physiol. 2019 Nov;234(11):20584-20602
pubmed: 31016756
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Oncoimmunology. 2017 Apr 20;6(6):e1317420
pubmed: 28680750
Breast Cancer Res Treat. 2012 Apr;132(3):793-805
pubmed: 21562709
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
Oncoimmunology. 2015 Jun 24;5(1):e1063772
pubmed: 26942079
J Exp Med. 2003 Feb 3;197(3):387-93
pubmed: 12566422
Patholog Res Int. 2014;2014:507512
pubmed: 24693457
APMIS. 2018 Mar;126(3):201-207
pubmed: 29484748
Am J Pathol. 1996 Mar;148(3):701-6
pubmed: 8774125
Oncotarget. 2017 Aug 1;8(45):79809-79815
pubmed: 29108362
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Int J Cancer. 2020 Mar 1;146(5):1421-1434
pubmed: 31709531
Cancer Med. 2018 Mar;7(3):690-697
pubmed: 29468834
Oncotarget. 2018 Sep 14;9(72):33719-33733
pubmed: 30263098
Cancer. 1983 Jul 1;52(1):126-30
pubmed: 6850535
Ann Oncol. 2015 May;26(5):873-879
pubmed: 25725046
J Immunother Cancer. 2018 Nov 23;6(1):129
pubmed: 30470260
Br J Cancer. 2015 Jun 30;113(1):150-8
pubmed: 26022929
Clin Cancer Res. 2008 Apr 15;14(8):2413-20
pubmed: 18413832
Nat Immunol. 2018 Jan;19(1):10-19
pubmed: 29242543
Breast Cancer Res Treat. 2016 Jun;157(3):461-74
pubmed: 27249999
PLoS Med. 2016 Dec 13;13(12):e1002194
pubmed: 27959923
Eur J Cancer. 2017 Aug;81:135-137
pubmed: 28624693
Pathol Oncol Res. 2020 Jan;26(1):317-325
pubmed: 30225783
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 1987 Jan;55(1):75-6
pubmed: 3814479